David Liu (DRL) is a co-founder and consultant for Editas Medicine, Pairwise Plants, Beam Therapeutics, Exo Therapeutics, and Prime Medicine. He owns founders’ equity in these companies, receives consultancies from them, and serves on their scientific advisory boards. He also serves as a scientific advisory board member of Tevard Biosciences and of Wuxi Biologics, and owns equity in the former. DRL may receive honoraria and travel reimbursements for some speaking engagements. He is a co-inventor on patents related to his research, as listed on his CV at https://liugroup.us. Some of these patents have been licensed to companies including those listed above. Potential conflicts of interest between his academic activities and his activities with other entities including the companies above are actively disclosed and managed in accordance with the conflict of interest policies of the Broad Institute, Harvard University, and HHMI.
The policies are available at: